Emile Voest
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.
Back to newsMore news
Collaboration between Hartwig and CKB makes both parties stronger
Hartwig Medical Foundation has worked with The Jackson Laboratory (JAX) Clinical Knowledgebase (CKB) team since 2020, to the benefit of …
22 impactful scientific publications in 2022
In 2022, research groups from all over the world published 22 scientific papers in which data from the Hartwig Medical …
Hartwig tools now available as a nextflow nf-core pipeline called oncoanalyser
The University of Melbourne Centre for Cancer Research (UMCCR) Genomics Platform Group, led by Professor Oliver Hofmann, has collaborated with …
In our profession, we need to know everything about the patient, but we also want to know as much as possible about the patient’s tumor.